Tourmaline Bio, Inc. (TRML)

Market Cap	521.57M
Revenue (ttm)	n/a
Net Income (ttm)	-63.88M
Shares Out	25.64M
EPS (ttm)	-2.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188,794
Open	19.97
Previous Close	19.87
Day's Range	19.14 - 20.65
52-Week Range	12.12 - 48.31
Beta	n/a
Analysts	Strong Buy
Price Target	54.00 (+165.49%)
Earnings Date	Nov 7, 2024

About TRML

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: TRML
• Website: https://www.tourmalinebio.com

Analyst Forecast

According to 6 analysts, the average rating for TRML stock is "Strong Buy." The 12-month stock price forecast is $54.0, which is an increase of 165.49% from the latest price.

Price Target

$54.0

(165.49% upside)

Analyst Consensus: Strong Buy